Inquiries by Email
WhatsApp Reservation
Stem cell therapy for kidney disease is an intravenous treatment approach that uses mesenchymal stem cells to calm the inflammation and vascular damage that drive chronic kidney disease (CKD) — used alongside standard nephrology care, never instead of it.
Below: what human clinical trials actually show (including where results were neutral), why diabetes and artery disease sit behind most kidney decline, who is and isn’t a candidate, and how Japan’s MHLW-regulated framework differs from low-cost stem cell tourism.
At Cell Grand Clinic in Osaka, kidney-related concerns are addressed within our regenerative medicine programs for diabetes and arteriosclerosis — up to 100–200 million of your own adipose-derived stem cells, cultured over 7 weeks and delivered by IV. Never pooled from donors.
15 MHLW-notified regenerative medicine treatment plans. NIH-trained, ABRM board-certified physician. Over 3,000 treatments across ~20 countries.
Reach us directly — WhatsApp and email inquiries are free of charge.
- What Stem Cell Therapy for Kidney Disease Can — and Cannot — Do
- Why Kidneys Fail: Diabetes and Artery Disease Sit Behind Most CKD
- Stem Cell Therapy for Kidney Disease: What Clinical Trials Show
- Stem Cells for Diabetic Nephropathy: The Best-Studied Kidney Lane
- Stem Cells for Kidney Failure: What Is Realistic at Each Stage
- How Kidney-Focused Regenerative Care Works in Japan
- How Much Does Stem Cell Therapy for Kidney Disease Cost?
- Who Is — and Is Not — a Candidate
- FAQ: Stem Cell Therapy for Kidney Disease
- Related Reading
- References
What Stem Cell Therapy for Kidney Disease Can — and Cannot — Do
Chronic kidney disease affects roughly one in ten adults worldwide, and once kidney function starts falling, conventional care is built around slowing the decline: blood-pressure and blood-sugar control, SGLT2 inhibitors, diet, and eventually dialysis or transplant. Nothing in the standard toolkit repairs the kidney itself. That gap is why patients search for stem cell options — and it deserves a precise answer rather than a sales pitch.
The honest summary: in human trials to date, mesenchymal stem cell (MSC) therapy has consistently proven safe, and in diabetic kidney disease it has shown signals of slowing the rate of eGFR decline compared with placebo. What no trial has yet shown is regeneration of a failed kidney, recovery from dialysis, or a cure. If a clinic anywhere promises those things, walk away. What a well-run program can honestly offer is an adjunct that targets the inflammation and blood-vessel damage driving the decline — on top of, never instead of, your nephrologist’s care.
Why Kidneys Fail: Diabetes and Artery Disease Sit Behind Most CKD
The two dominant causes of CKD worldwide are diabetes and hypertension with arteriosclerosis. High glucose injures the filtering units (glomeruli) and the small vessels that feed them; stiffened, narrowed arteries starve the kidney of blood flow. In both cases the kidney is often the victim of a body-wide metabolic and vascular disease — which is why treating “the numbers on the kidney panel” in isolation rarely works.
This is also how treatment is organized at our clinic: kidney-related concerns are addressed within our regenerative medicine programs for diabetes and arteriosclerosis — the upstream conditions doing the damage — rather than as an isolated “kidney shot.” If your creatinine is creeping up and you have diabetes, prediabetes, high blood pressure or known artery disease, those are the frameworks under which a physician can properly evaluate what regenerative medicine can contribute.
Stem Cell Therapy for Kidney Disease: What Clinical Trials Show
Human data in CKD is younger and smaller than in joints or skin, but several placebo-controlled and safety trials have now been published. Here is the evidence, including the neutral results:
| Study | Cells & design | What it found |
|---|---|---|
| NEPHSTROM Perico 2023 · Phase 1b/2a RCT |
Allogeneic bone-marrow MSC (ORBCEL-M), single IV infusion of 80 million cells 16 adults · type 2 diabetes with progressive kidney disease |
Safe · slower eGFR decline vs placebo Median annual rate of eGFR decline significantly slower than placebo (by eGFR; measured GFR did not differ). Regulatory T cells were preserved. |
| NEPHSTROM 2026 Perico 2026 · Randomized controlled trial |
Allogeneic MSC infusion in diabetic kidney disease (expanded randomized data) Published in Kidney International Reports |
Full randomized results · 2026 Extends the NEPHSTROM program with the complete randomized dataset. |
| Packham 2016 RCT · dose escalation |
Allogeneic mesenchymal precursor cells (rexlemestrocel-L), single IV, 150 or 300 million cells 30 adults · diabetic nephropathy, eGFR 20–50 |
Safe · trend toward stable eGFR No treatment-related serious adverse events. Trend toward stabilized or improved eGFR/mGFR at 12 weeks vs placebo — suggestive, not definitive (not powered for efficacy). |
| Makhlough 2018 Single-arm safety study |
Autologous bone-marrow MSC, single IV, 1–2 million cells/kg 7 patients · CKD of mixed cause · 18-month follow-up |
Safe · eGFR change not significant No cell-related adverse events. A neutral efficacy result worth stating plainly. |
| Makhlough 2017 Phase 1 · ADPKD |
Autologous bone-marrow MSC, single IV, 2 million cells/kg 6 patients · polycystic kidney disease |
Safe · no significant eGFR change Safe and tolerable over 12 months; kidney-function trends did not reach significance. |
How to read this table. Three things stand out. First, intravenous MSC therapy has a consistent safety record in kidney patients, including autologous (your-own-cell) protocols that need no immunosuppression. Second, the efficacy signal that exists is about slowing decline — a meaningful goal for a disease measured in years — not about rebuilding lost nephrons. Third, the strongest data comes specifically from diabetic kidney disease, which is exactly where the biological rationale (inflammation plus vascular damage) is clearest. Larger phase 2 trials are ongoing, and the field remains at the research stage for efficacy.
Reach us directly — WhatsApp and email inquiries are free of charge.
Stem Cells for Diabetic Nephropathy: The Best-Studied Kidney Lane
Diabetic nephropathy — kidney damage from long-standing diabetes — is the leading cause of end-stage kidney failure worldwide, and it is where stem cell research has concentrated. Both randomized trials above (NEPHSTROM and Packham) were run specifically in diabetic kidney disease, and both point the same direction: IV mesenchymal cell therapy is safe and may slow the fall in filtration rate.
Biologically this makes sense. In diabetic nephropathy the enemy is not one dead structure but an ongoing process: chronic inflammation, fibrosis, and damage to the small vessels of the glomeruli. MSCs act on precisely those processes — secreting anti-inflammatory and anti-fibrotic factors and supporting vascular repair — which is also why the same cell therapy is studied for the metabolic control of diabetes itself. For a patient, the practical implication is that protecting the kidney and treating the diabetes are one project, not two.
Stem Cells for Kidney Failure: What Is Realistic at Each Stage
Can kidneys regenerate? Only to a limited degree. The kidney can repair some tubular injury, but nephrons — the filtering units — do not grow back once lost. That is the blunt reason “stem cell kidney regeneration” headlines need careful reading: in human trials, cell therapy supports and protects the kidney tissue you still have; it has not been shown to rebuild nephrons that are gone.
That biology dictates what is realistic at each stage. In early to mid-stage CKD (stages 2–3), there is the most remaining tissue to protect, and this is where slowing the decline has the greatest long-term payoff. In stage 4, evaluation is strictly case-by-case — the metabolic and vascular drivers can still be addressed, but expectations must be modest. In stage 5 kidney failure or on dialysis, there is no clinical evidence that stem cell therapy restores function or replaces dialysis; transplant evaluation and dialysis care remain the correct path, and we say so plainly.
How Kidney-Focused Regenerative Care Works in Japan
Japan regulates regenerative medicine under a dedicated national law: clinics must file treatment provision plans that are reviewed by certified committees and notified to the Ministry of Health, Labour and Welfare (MHLW). At Cell Grand Clinic in Osaka, kidney-related concerns are treated within our MHLW-notified treatment plans for diabetes (Plan No. PB5250050) and arteriosclerosis (Plan No. PB5250051) — the two conditions that drive most kidney decline. There is no exaggerated “kidney regeneration package”; there is a physician-led evaluation of your metabolic and vascular disease, with kidney function tracked as a key outcome.
The protocol itself: a small sample of your own adipose (fat) tissue is collected in Osaka, and your cells are cultured for about 7 weeks in a quality-controlled process (viability about 98%, identity-verified by flow cytometry, no donor pooling, no batch mixing). Up to 100–200 million autologous adipose-derived stem cells are then returned by IV infusion. Because the cells are your own, no immunosuppression is needed — a fundamental difference from the transplant-style approaches in the trials above. International patients complete this with two short visits to Osaka (about 3 days each), with consultations and follow-up handled directly in English by the treating physician.
What we will tell you honestly at consultation: stem cell therapy is an adjunct at the research stage for kidney outcomes. It does not replace your nephrologist, your blood-pressure medication, or dialysis planning if you need it. The realistic aim — supported by, but not yet proven by, the trial data — is to address the inflammatory and vascular drivers of decline while your standard care continues.
How Much Does Stem Cell Therapy for Kidney Disease Cost?
Overseas clinics that publish price lists — mostly in the United States, Mexico and Latin America — typically charge tens of thousands of US dollars for a donor-cell (umbilical-cord MSC) infusion package. Those figures are a useful market reference, but note what they usually describe: allogeneic cells from a donor, often outside a national regulatory framework for regenerative medicine.
At Cell Grand Clinic, autologous stem cell therapy starts from JPY 2,970,000 (approx. USD 19,800) per session for 100 million cells — tax included, with blood tests and adipose tissue collection covered. The appropriate program (diabetes or arteriosclerosis plan), the cell dose (up to 100–200 million autologous cells) and the number of infusions depend on your condition, so a personal quotation follows a medical review. Each cycle covers evaluation, tissue collection, 7-week individual culture, infusion and 1/3/6-month follow-up. An online consultation is JPY 55,000 per person and is credited toward treatment. Full details are on our pricing page; supportive options such as exosome and NMN therapy also have published prices. Contact us by WhatsApp or email for a specific quotation.
Japan vs. Mexico for Kidney Stem Cell Treatment
Many international patients compare Japan with Mexico or Tijuana clinics, and the differences are structural rather than cosmetic: Japan operates under a dedicated national law with MHLW-notified treatment plans and certified committee review; treatment here uses your own adipose-derived cells rather than donor cells; and the same physician handles your case from inquiry to 6-month follow-up. We compare the options for treatment destinations honestly — including cost logic and safety questions to ask any clinic — in our guide to getting stem cell therapy abroad safely.
Who Is — and Is Not — a Candidate
✅ A consultation makes sense if you:
- Have CKD stage 2–4 with diabetes, prediabetes, hypertension or known artery disease behind it
- Are watching creatinine rise or eGFR fall despite good standard care
- Have diabetic nephropathy and want to address the underlying metabolic-vascular disease
- Can travel to Osaka twice and continue nephrology care at home
⚠️ This is not for you if you:
- Are on dialysis and hoping to come off it — no trial supports that
- Have end-stage (stage 5) kidney failure — transplant and dialysis planning come first
- Expect a cure or guaranteed eGFR improvement
- Have active cancer or an uncontrolled infection
FAQ: Stem Cell Therapy for Kidney Disease
Can stem cells repair damaged kidneys?
Not in the sense of regrowing lost nephrons — no human trial has shown that. What randomized trials in diabetic kidney disease have shown is a consistent safety record and signals that IV mesenchymal stem cell therapy can slow the rate of eGFR decline compared with placebo. The realistic framing is protection and slowing, not repair.
Can stem cell therapy get me off dialysis?
No. There is no clinical evidence that stem cell therapy reverses established end-stage kidney failure or replaces dialysis. Patients already on dialysis are not candidates for that goal at our clinic, and we recommend treating any clinic promising this with extreme caution.
Is stem cell therapy for kidney disease safe?
In published trials — both allogeneic (donor) and autologous (your own cells) — IV MSC infusion in kidney patients produced no treatment-related serious adverse events. Autologous adipose-derived cells, as used in Japan, additionally avoid immunosuppression and donor-cell risks. Safety of the specific protocol is reviewed at consultation based on your health status.
What about diabetic nephropathy specifically?
Diabetic nephropathy is the best-studied kidney indication: both randomized trials to date (NEPHSTROM 2023, Packham 2016) enrolled diabetic kidney disease patients and reported safety with favorable eGFR-decline signals. At our clinic, diabetic nephropathy concerns are addressed within the diabetes treatment program, so the metabolic disease and the kidney are treated as one problem.
How is treatment arranged in Japan, and how many visits are needed?
Kidney-related care is provided within our MHLW-notified diabetes and arteriosclerosis treatment plans. International patients typically need two short visits to Osaka (about 3 days each): the first for evaluation and adipose tissue collection (about 7 weeks of cell culture follow), the second for the IV infusion. Online consultation, records review and 1/3/6-month follow-up are handled directly in English by the treating physician.
How much does stem cell therapy for kidney disease cost in Japan?
Autologous stem cell therapy at Cell Grand Clinic starts from JPY 2,970,000 (approx. USD 19,800) per session for 100 million cells, tax included, with blood tests and adipose tissue collection covered. The final quotation depends on the program (diabetes or arteriosclerosis plan), cell dose and number of infusions, and is provided after a medical review. An online consultation is JPY 55,000 per person and is credited toward treatment; supportive options such as exosome therapy have published prices on our site.
Can kidneys regenerate on their own?
Only partially. The kidney can recover from some acute tubular injury, but lost nephrons do not grow back. This is why protecting remaining function and slowing decline — not regrowth — is the realistic goal of any kidney therapy today, including stem cell therapy.
Can stem cells cure kidney disease?
No. No clinical trial has shown that stem cells cure chronic kidney disease. The published evidence shows safety and signals of slower eGFR decline in diabetic kidney disease. Any clinic promising a cure for CKD should be treated with caution.
Reach us directly — WhatsApp and email inquiries are free of charge.
Related Reading
Last medically reviewed: October 2026. Author: Dr. Yuichi Wakabayashi, MD, PhD (NIH-trained, ABRM board-certified).
References
- Perico N, et al. Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial (NEPHSTROM). J Am Soc Nephrol. 2023;34(10):1733-1751. PMID: 37560967
- Perico N, et al. Randomized Controlled Clinical Trial of Allogeneic Mesenchymal Stromal Cell Infusion in Diabetic Kidney Disease. Kidney Int Rep. 2026;11(8):106628. PMID: 42433663
- Packham DK, et al. Allogeneic Mesenchymal Precursor Cells (MPC) in Diabetic Nephropathy: A Randomized, Placebo-controlled, Dose Escalation Study. EBioMedicine. 2016;12:263-269. PMID: 27743903
- Makhlough A, et al. Bone marrow-mesenchymal stromal cell infusion in patients with chronic kidney disease: A safety study with 18 months of follow-up. Cytotherapy. 2018;20(5):660-669. PMID: 29580865
- Makhlough A, et al. Safety and tolerability of autologous bone marrow mesenchymal stromal cells in ADPKD patients. Stem Cell Res Ther. 2017;8(1):116. PMID: 28535817
Updated: 2026.10.06
